TW202308631A - 用於治療mpnst之化合物和組成物 - Google Patents

用於治療mpnst之化合物和組成物 Download PDF

Info

Publication number
TW202308631A
TW202308631A TW111116420A TW111116420A TW202308631A TW 202308631 A TW202308631 A TW 202308631A TW 111116420 A TW111116420 A TW 111116420A TW 111116420 A TW111116420 A TW 111116420A TW 202308631 A TW202308631 A TW 202308631A
Authority
TW
Taiwan
Prior art keywords
day
amino
mpnst
inhibitor
cdk4
Prior art date
Application number
TW111116420A
Other languages
English (en)
Chinese (zh)
Inventor
郝淮湘
蘇珊 穆迪
克里斯汀 普拉提拉斯
王珈婉
Original Assignee
瑞士商諾華公司
美國約翰赫金斯大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商諾華公司, 美國約翰赫金斯大學 filed Critical 瑞士商諾華公司
Publication of TW202308631A publication Critical patent/TW202308631A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW111116420A 2021-05-05 2022-04-29 用於治療mpnst之化合物和組成物 TW202308631A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163184422P 2021-05-05 2021-05-05
US63/184,422 2021-05-05

Publications (1)

Publication Number Publication Date
TW202308631A true TW202308631A (zh) 2023-03-01

Family

ID=81598046

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111116420A TW202308631A (zh) 2021-05-05 2022-04-29 用於治療mpnst之化合物和組成物

Country Status (6)

Country Link
US (1) US20240238284A1 (cg-RX-API-DMAC7.html)
EP (1) EP4333847A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024517788A (cg-RX-API-DMAC7.html)
CN (1) CN117177752A (cg-RX-API-DMAC7.html)
TW (1) TW202308631A (cg-RX-API-DMAC7.html)
WO (1) WO2022234409A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100883289B1 (ko) 2004-06-11 2009-02-11 니뽄 다바코 산교 가부시키가이샤 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2h-피리도[2,3-d]피리미딘 유도체 및 관련 화합물
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
IL311645B2 (en) 2016-07-12 2025-11-01 Revolution Medicines Inc 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors
TWI852912B (zh) * 2017-09-07 2024-08-21 美商銳新醫藥公司 Shp2抑制劑組合物以及治療癌症的方法
US12343344B2 (en) * 2019-02-12 2025-07-01 Novartis Ag Pharmaceutical combination comprising TNO155 and ribociclib

Also Published As

Publication number Publication date
US20240238284A1 (en) 2024-07-18
WO2022234409A1 (en) 2022-11-10
CN117177752A (zh) 2023-12-05
EP4333847A1 (en) 2024-03-13
JP2024517788A (ja) 2024-04-23

Similar Documents

Publication Publication Date Title
AU2020222296B2 (en) Pharmaceutical combination comprising TNO155 and ribociclib
TW202146021A (zh) 包含達拉菲尼、erk抑制劑和shp2抑制劑之三重藥物組合
EP3924053A1 (en) Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
AU2019315466B2 (en) Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP
US20160129003A1 (en) Pharmaceutical Combinations
AU2021267213B2 (en) Pharmaceutical combination comprising TNO155 and nazartinib
WO2012055015A1 (en) Combination comprising an atp analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer
JP2025000847A (ja) がんを処置するための薬学的組合せ
US20240238284A1 (en) Compounds and compositions for the treatment of mpnst
HK40060474A (en) Pharmaceutical combination comprising tno155 and ribociclib